Atıf İçin Kopyala
GÜMÜŞ M., Ozgur A., Tutar L., DİŞLİ A., KOCA İ., TUTAR Y.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, cilt.17, sa.14, ss.1231-1245, 2016 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
17
Sayı:
14
-
Basım Tarihi:
2016
-
Doi Numarası:
10.2174/1389201017666161031105815
-
Dergi Adı:
CURRENT PHARMACEUTICAL BIOTECHNOLOGY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.1231-1245
-
Anahtar Kelimeler:
Benzodiazepine, cancer, bone cancer, Hsp90, client proteins, HSP90, GELDANAMYCIN, ANGIOGENESIS, DISCOVERY, OXAZEPINE, 3-KINASE, STRATEGY
-
Gazi Üniversitesi Adresli:
Evet
Özet
Background: Despite development of novel cancer drugs, invasive ductal breast carcinoma and its metastasis are still highly morbid. Therefore, new therapeutic approaches are being developed and Hsp90 is an important target for drug design. For this purpose, a series of benzodiazepine derivatives were designed and synthesized as novel Hsp90 inhibitor.